Publication:
Heterologous gam-COVID-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than homologous sputnik V in a real-world data analysis.

Loading...
Thumbnail Image

Date

2022-05-17

Authors

Pereson, Matías J
Amaya, Lucas
Neukam, Karin
Baré, Patricia
Echegoyen, Natalia
Badano, María Noel
Lucero, Alicia
Martelli, Antonella
Garcia, Gabriel H
Videla, Cristina

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

To compare the homologous prime-boost vaccination scheme of Gam-COVID-Vac (Sputnik V (SpV)) to its heterologous combination with mRNA-1273 (Moderna (Mod)) vaccine. SARS-CoV-2 anti-spike (S)-receptor binding domain (RBD) IgG concentration was assessed three to seven weeks after complete vaccination. Reactogenicity was evaluated by declared side events and medical assistance required until day 7 post boost. Of 190 participants enrolled, 105 received homologous SpV/SpV and the remaining heterologous SpV/Mod vaccination scheme, respectively. Median (interquartile range (IQR)) age was 54 (37-63) years, 132 out of 190 (69.5%) were female, and 46 out of 190 (24.2%) individuals had a prior confirmed COVID-19. Anti-S-RBD IgG median (IQR) titers were significantly higher for SpV/Mod (2511 (1476-3992) binding antibody units (BAU)/mL) than for SpV/SpV (582 (209-1609) BAU/mL; p  The heterologous SpV/Mod combination against SARS-CoV-2 is well tolerated and significantly increases humoral immune response as compared to the homologous SpV/SpV immunization.

Description

MeSH Terms

2019-nCoV Vaccine mRNA-1273
Antibodies, Viral
COVID-19
COVID-19 Vaccines
Data Analysis
Female
Humans
Immunoglobulin G
Male
Middle Aged
SARS-CoV-2

DeCS Terms

CIE Terms

Keywords

Gam-COVID-Vac, Heterologous scheme, SARS-CoV-2, Vaccine, mRNA-1273

Citation